Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

1(33.3%)

Phase 3

1(33.3%)

N/A

1(33.3%)

3Total

Phase 2(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01028053Phase 3Completed

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

Role: collaborator

NCT00550797Phase 2Completed

Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma

Role: collaborator

NCT01287351Completed

Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study

Role: collaborator

NCT01049399Not ApplicableCompleted

Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

Role: collaborator

All 4 trials loaded